Αποτελέσματα Αναζήτησης
To find a site near you, please enter your location. View Trial Details. Condition. Moderna ID. mRNA-1403-P301. NCT ID. NCT06592794. Trial Title. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis.
28 Δεκ 2017 · In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma...
11 Μαΐ 2023 · In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL).
25 Ιαν 2023 · In this study, effectiveness against hospitalization or death was 24.9% after a monovalent booster and 61.8% after a bivalent booster. Protection has waned over time.
ZUMA-1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi-cel), an autologous CD19-directed chimaeric antigen receptor (CAR)-T cell therapy, in refractory large B-cell lymphoma. To reduce treatment-related toxicity, several exploratory safety management cohorts were added to ZUMA-1.
These results supported the recent approval of axi-cel by the US FDA for the treatment of adult pts with relapsed or refractory large B cell lymphoma after ≥ 2 prior lines of systemic therapy. Here, we assessed outcomes of axi-cel by prior lines of therapy (LoT) in pts from Phases 1 and 2 of ZUMA-1.
5 Ιουν 2023 · In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous...
